X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23589) 23589
Newspaper Article (3454) 3454
Newsletter (1022) 1022
Publication (1011) 1011
Magazine Article (412) 412
Book Review (315) 315
Book Chapter (218) 218
Trade Publication Article (210) 210
Web Resource (75) 75
Conference Proceeding (42) 42
Book / eBook (36) 36
Transcript (28) 28
Dissertation (7) 7
Data Set (4) 4
Report (3) 3
Reference (2) 2
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17075) 17075
dermatitis (9724) 9724
female (9114) 9114
male (8753) 8753
dermatology (8573) 8573
index medicus (8566) 8566
atopic dermatitis (6472) 6472
adult (6025) 6025
skin (5272) 5272
middle aged (4726) 4726
animals (4443) 4443
dermatitis, atopic - drug therapy (3998) 3998
allergy (2927) 2927
inflammation (2898) 2898
atopic-dermatitis (2846) 2846
aged (2803) 2803
adolescent (2802) 2802
child (2787) 2787
immunology (2588) 2588
drug therapy (2527) 2527
treatment outcome (2449) 2449
psoriasis (2411) 2411
administration, topical (2314) 2314
eczema (2186) 2186
skin diseases (2133) 2133
care and treatment (2059) 2059
mice (2031) 2031
research (1841) 1841
asthma (1713) 1713
child, preschool (1691) 1691
children (1659) 1659
patients (1603) 1603
clinical trials (1572) 1572
dermatitis - drug therapy (1495) 1495
disease (1461) 1461
health aspects (1433) 1433
pharmacology & pharmacy (1425) 1425
infant (1399) 1399
cytokines (1389) 1389
analysis (1358) 1358
skin - pathology (1348) 1348
pediatrics (1345) 1345
pruritus (1296) 1296
pharmaceutical industry (1225) 1225
severity of illness index (1217) 1217
dermatitis, atopic - immunology (1204) 1204
diagnosis, differential (1148) 1148
double-blind (1148) 1148
allergies (1077) 1077
administration, cutaneous (1054) 1054
medical research (1045) 1045
skin - drug effects (1036) 1036
anti-inflammatory agents - therapeutic use (1032) 1032
therapy (1032) 1032
young adult (1015) 1015
dermatitis, allergic contact - etiology (1013) 1013
diagnosis (999) 999
double-blind method (994) 994
risk factors (994) 994
psoriasis - drug therapy (962) 962
quality of life (961) 961
dermatologic agents - therapeutic use (947) 947
expression (931) 931
immunosuppressive agents - therapeutic use (905) 905
dermatology & venereal diseases (901) 901
ointments (900) 900
efficacy (897) 897
corticosteroids (885) 885
studies (871) 871
patch tests (856) 856
disease models, animal (854) 854
medicine & public health (833) 833
dermatitis, contact - drug therapy (827) 827
medicine (826) 826
oncology (826) 826
dermatitis, atopic - pathology (811) 811
dermatitis, contact - etiology (802) 802
allergic contact dermatitis (801) 801
veterinary sciences (788) 788
medicine, general & internal (779) 779
drug eruptions - etiology (777) 777
medicine, experimental (771) 771
dogs (761) 761
administration, oral (758) 758
skin diseases - drug therapy (753) 753
contact dermatitis (752) 752
management (748) 748
time factors (744) 744
dermatologic agents (730) 730
dermatitis, atopic - therapy (729) 729
dermatitis, seborrheic - drug therapy (728) 728
immunotherapy (715) 715
drugs (712) 712
cancer (706) 706
tacrolimus (700) 700
prevalence (696) 696
chronic disease (693) 693
follow-up studies (693) 693
fda approval (692) 692
immunoglobulin e (684) 684
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Online Resources - Online (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Gerstein Science - Periodical Stacks (1) 1
Scarborough Hospital - General (1) 1
Women's College Hospital - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26596) 26596
German (926) 926
French (425) 425
Japanese (292) 292
Russian (274) 274
Spanish (155) 155
Italian (141) 141
Polish (134) 134
Dutch (43) 43
Danish (37) 37
Chinese (33) 33
Korean (29) 29
Portuguese (22) 22
Czech (17) 17
Swedish (17) 17
Norwegian (14) 14
Hungarian (12) 12
Finnish (11) 11
Ukrainian (11) 11
Croatian (9) 9
Turkish (8) 8
Romanian (7) 7
Hebrew (6) 6
Arabic (4) 4
Afrikaans (2) 2
Slovak (2) 2
Bulgarian (1) 1
Greek (1) 1
Icelandic (1) 1
Serbian (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 02/2019, Volume 58, Issue Supplement_1, pp. i43 - i54
Abstract Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules associated with one of the major pathways... 
FILGOTINIB GLPG0634/GS-6034 | CROHNS-DISEASE | INADEQUATE RESPONSE | PHASE-III | STAT pathway | RHEUMATOLOGY | LONG-TERM EXTENSION | ALOPECIA-AREATA | immune-mediated diseases | CHRONIC PLAQUE PSORIASIS | JAK | JANUS KINASE INHIBITOR | DOUBLE-BLIND | JAK inhibitors | TOFACITINIB-TREATED PATIENTS | Spondylarthropathies - drug therapy | Chilblains - drug therapy | Humans | Dental Enamel Hypoplasia - drug therapy | Metacarpus - abnormalities | Osteoporosis - drug therapy | Immunologic Deficiency Syndromes | Arthritis, Rheumatoid - drug therapy | Lupus Erythematosus, Cutaneous - drug therapy | Arthritis, Psoriatic - drug therapy | Muscular Diseases - drug therapy | Autoimmune Diseases - drug therapy | Inflammatory Bowel Diseases - drug therapy | Psoriasis - drug therapy | Cytokines | Uveitis - drug therapy | Giant Cell Arteritis - drug therapy | Vascular Calcification - drug therapy | Autoimmune Diseases of the Nervous System - drug therapy | Aortic Diseases - drug therapy | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Janus Kinase Inhibitors - therapeutic use | Odontodysplasia - drug therapy | Nervous System Malformations - drug therapy | Phosphorylation | Transcription factors | Transcription | Clinical trials | Inflammation | Immunosuppressive agents | Signal transduction | Alopecia | Atopic dermatitis | Rheumatoid arthritis | Janus kinase | Skin diseases | Transduction | Growth factors | Reviews
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 901 - 901
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 71 - 81
[Display omitted] Andrographis paniculata has long been part of the traditional herbal medicine system in Asia and in Scandinavia. Andrographolide was isolated... 
Hepatitis | NF-κB | Autoimmune | Neurodegeneration | Nrf2 | Asthma | OXIDATIVE STRESS | ALZHEIMERS-DISEASE | COGNITIVE IMPAIRMENT | CELL-CYCLE ARREST | PROTECTIVE ACTIVITY | IN-VITRO | NF-kappa B | INDUCED PULMONARY-FIBROSIS | SIGNALING PATHWAY | PHARMACOLOGY & PHARMACY | COMBINATION KAN-JANG | NF-KAPPA-B | Liver Cirrhosis - immunology | Humans | Drugs, Investigational - therapeutic use | NF-E2-Related Factor 2 - agonists | Protective Agents - chemistry | Neurodegenerative Diseases - drug therapy | Hepatitis - drug therapy | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Hepatitis - metabolism | Pneumonia - immunology | Autoimmune Diseases - metabolism | Autoimmune Diseases - drug therapy | Diterpenes - pharmacology | Chemical and Drug Induced Liver Injury - prevention & control | NF-kappa B p50 Subunit - antagonists & inhibitors | NF-kappa B p50 Subunit - metabolism | Autoimmune Diseases - prevention & control | Chemical and Drug Induced Liver Injury - immunology | Signal Transduction - drug effects | Chemical and Drug Induced Liver Injury - metabolism | Models, Biological | NF-E2-Related Factor 2 - metabolism | Oxidative Stress - drug effects | Pneumonia - metabolism | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Dermatitis - immunology | Neurodegenerative Diseases - prevention & control | Protective Agents - metabolism | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors | Protective Agents - therapeutic use | Neurodegenerative Diseases - immunology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Drugs, Investigational - chemistry | Hepatitis - prevention & control | Drug Design | Liver Cirrhosis - metabolism | Diterpenes - chemistry | Liver Cirrhosis - drug therapy | Diterpenes - therapeutic use | Liver Cirrhosis - prevention & control | Autoimmune Diseases - immunology | Dermatitis - prevention & control | Neurodegenerative Diseases - metabolism | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Pneumonia - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | NF-kappa B p50 Subunit - chemistry | Hepatitis - immunology | Diterpenes - adverse effects | Dermatitis - drug therapy | Dermatitis - metabolism | Antioxidants | Medical colleges | Lead compounds | Drug discovery | Anti-inflammatory drugs | Analysis | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 01/2008, Volume 111, Issue 2, pp. 566 - 573
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 02/2016, Volume 17, Issue 2, pp. 160 - 160
Phenolic compounds constitute a group of secondary metabolites which have important functions in plants. Besides the beneficial effects on the plant host,... 
Antimicrobial | Wound healing | Anti-carcinogenic | Anti-aging properties | Skin diseases | Antioxidant | Phenolic compounds | Anti-inflammatory | antimicrobial | wound healing | antioxidant | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | phenolic compounds | CELL APOPTOSIS | CHEMISTRY, MULTIDISCIPLINARY | ANTIOXIDANT ACTIVITY RELATIONSHIPS | TYROSINASE INHIBITORY-ACTIVITIES | anti-carcinogenic | anti-aging properties | ATOPIC-DERMATITIS | IN-VITRO | REACTIVE OXYGEN | CAFFEIC ACID | MATRIX METALLOPROTEINASE-1 | anti-inflammatory | skin diseases | Plant Extracts - chemistry | Antioxidants - chemistry | Plant Extracts - pharmacology | Skin - metabolism | Anti-Infective Agents - pharmacology | Humans | Cellular Senescence - drug effects | Skin Diseases - pathology | Skin Diseases - prevention & control | Anti-Infective Agents - chemistry | Anti-Inflammatory Agents - therapeutic use | Burns - metabolism | Wound Healing - drug effects | Skin - pathology | Burns - drug therapy | Phenols - pharmacology | Skin Diseases - metabolism | Anti-Inflammatory Agents - pharmacology | Anti-Infective Agents - therapeutic use | Skin Diseases - drug therapy | Antioxidants - pharmacology | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents - chemistry | Burns - pathology | Phenols - therapeutic use | Phenols - chemistry | Oxidative Stress - drug effects | Plant Extracts - therapeutic use | Skin - drug effects | Antioxidants | Disease prevention | Phenols | Phytochemicals
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 203 - 218
There has been a rapid emergence of numerous targeted agents in the oncology community in the last decade. This exciting paradigm shift in drug development... 
Vandetanib | Panitumumab | Multikinase inhibitors | Bevacizumab | Macular eruption | Pigment changes | Paronychia | Supportive oncodermatology | Drug eruption | Sunitinib | Lapatinib | Cetuximab | Gefitinib | Vascular endothelial growth factor | Pazopanib | Dasatinib | Photosensitivity | Imatinib | Mucositis | Morbilliform | Chemotherapy | Side effects | Stomatitis | Alopecia | Disturbed wound healing | Erlotinib | Sorafenib | KIT | Monoclonal antibodies | Dry skin | Nilotinib | Drug rash | Targeted therapy | erbB receptor | Toxic erythema | Papulopustular eruption | Hyperkeratotic handefoot skin reaction | Antiangiogenic agents | Platelet-derived growth factor receptor | Ranibizumab | Small molecule | Cutaneous adverse effects | Drug reaction | Epidermal growth factor receptor inhibitors | Mucocutaneous hemorrhage | Cancer treatment | Dermatologic toxicities | BCR-ABL | Xerosis | Canertinib | Tyrosine kinase inhibitors | Dual kinase inhibitors | Adverse sequelae | Genital rash | Anticancer | HER2 | cancer treatment | small molecule | sorafenib | morbilliform | photosensitivity | lapatinib | panitumumab | xerosis | chemotherapy | METASTATIC COLORECTAL-CANCER | mucocutaneous hemorrhage | canertinib | IMATINIB-INDUCED ERYTHRODERMA | bevacizumab | side effects | drug reaction | FOOT SKIN REACTION | sunitinib | papulopustular eruption | cetuximab | imatinib | gefitinib | drug rash | alopecia | EPIDERMAL-GROWTH-FACTOR | dry skin | disturbed wound healing | ADVANCED HEPATOCELLULAR-CARCINOMA | CHRONIC MYELOGENOUS LEUKEMIA | pigment changes | paronychia | stomatitis | dual kinase inhibitors | cutaneous adverse effects | anticancer | ranibizumab | epidermal growth factor receptor inhibitors | DERMATOLOGY | hyperkeratotic hand-foot skin reaction | tyrosine kinase inhibitors | antiangiogenic agents | dermatologic toxicities | drug eruption | multikinase inhibitors | dasatinib | nilotinib | platelet-derived growth factor receptor | adverse sequelae | supportive oncodermatology | targeted therapy | genital rash | FACTOR RECEPTOR INHIBITORS | macular eruption | toxic erythema | erlotinib | pazopanib | CHRONIC MYELOID-LEUKEMIA | EYELASH TRICHOMEGALY SECONDARY | mucositis | vandetanib | vascular endothelial growth factor | PLACEBO-CONTROLLED TRIAL | monoclonal antibodies | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Humans | Drug Eruptions - therapy | Mucositis - chemically induced | Dose-Response Relationship, Drug | Dermatitis, Photoallergic - etiology | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug Eruptions - diagnosis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Hair Diseases - chemically induced | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Alopecia - chemically induced | Angiogenesis Inhibitors - adverse effects | Cell Membrane - drug effects | Index Medicus
Journal Article